N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis

Wan-Xin Peng; Fei Liu; Jia-Hong Jiang; Hang Yuan; Ziqiang Zhang; Liu Yang; Yin-Yuan Mo

doi:10.1016/j.gendis.2022.02.014

您当前的位置：

首页 >

文章列表页 >

N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis

更新时间：2023-05-16

- N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis
- Genes & Diseases Vol. 10, Issue 2, (2023)
- 作者机构：
  
  1. Department of Colorectal Surgery, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College,Zhejiang,Hangzhou,China,310014
  2. Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College,Zhejiang,Hangzhou,China,310014
  3. Department of Nephrology, The Children's Hospital, Zhejiang University School of Medicine, National Research Center for Child Health,Zhejiang,Hangzhou,China,310052
  4. Department of Surgical Oncology, The Children's Hospital, Zhejiang University School of Medicine, National Research Center for Child Health,Zhejiang,Hangzhou,China,310052
  5. Department of Medical Oncology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College,Zhejiang,Hangzhou,China,310014
  6. Department of Pulmonary Medicine, Tongji Hospital, Tongji University,Shanghai,China,200065
  7. Cancer Center and Research Institute, University of Mississippi Medical Center,MS,Jackson,USA,39216
  8. Department of Pharmacology/Toxicology, University of Mississippi Medical Center,MS,Jackson,USA,39216
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2022.02.014
  CLC：
- Published：2023，
  
  Published Online：1 March 2023，
扫描看全文
Wan-Xin Peng, Fei Liu, Jia-Hong Jiang, et al. N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis. [J]. Genes & Diseases 10(2).(2023)
DOI：

Wan-Xin Peng, Fei Liu, Jia-Hong Jiang, et al. N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis. [J]. Genes & Diseases 10(2).(2023) DOI： 10.1016/j.gendis.2022.02.014.

摘要

Abstract

umulating evidence indicates that RNA methylation at N

-methyladenosine (m6A) plays an important regulatory role in gene expression and aberrant mRNA m6A modification is often associated with a variety of cancers. However

little is known whether and how m6A-modification impacts long non-coding RNA (lncRNA) and lncRNA-mediated tumorigenesis

particularly in pancreatic ductal adenocarcinoma (PDAC). In the present study

we report that a previously uncharacterized lncRNA

LINC00901

promotes pancreatic cancer cell growth and invasion and moreover

LINC00901 is subject to m6A modification which regulates its expression. In this regard

YTHDF1 serves as a reader for the m6A modified LINC00901 and downregulates the LINC00901 level. Notably

two conserved m6A sites in LINC00901 are critical to the recognition of LINC00901 by YTHDF1. Finally

RNA sequencing (RNA-seq) and gene function analysis revealed that LINC00901 positively regulates MYC through upregulation of IGF2BP2

a known RNA binding protein that can enhance MYC mRNA stability. Together

our results suggest that there is a LINC00901-IGF2BP2-MYC axis through which LINC00901 promotes PDAC progression in an m6A dependent manner.

关键词

Keywords

IGF2BP2LINC00901MYCN6-methyladenosine modification (m6A)PDACYTHDF1

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

The m6A regulator KIAA1429 stabilizes RAB27B mRNA and promotes the progression of chronic myeloid leukemia and resistance to targeted therapy

BET in hematologic tumors: Immunity, pathogenesis, clinical trials and drug combinations

Regulation mechanism and pathogenic role of lncRNA plasmacytoma variant translocation 1 (PVT1) in human diseases

PTPN18 promotes colorectal cancer progression by regulating the c-MYC-CDK4 axis

M6A modification of circNSUN2 promotes colorectal liver metastasis

Related Author

Xiaozhong Wang

Bo Huang

Yanmei Xu

Meiyong Li

Shuqi Li

Jing Zhang

Jin Lin

Jing Liu

Related Institution

Jiangxi Province Key Laboratory of Laboratory Medicine, Jiangxi Provincial Clinical Research Center for Laboratory Medicine, Department of Clinical Laboratory, The Second Affiliated Hospital of Nanchang University

Department of Hematology, The Affiliated Hospital of Southwest Medical University

Department of Hematology, Lanzhou University Second Hospital

Biomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

Department of Endocrinology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

⁰